Shanghai CRO Service Alliance Adds Clinical Development Capabilities

SHANGHAI, China, April 30 /Xinhua-PRNewswire/ -- Today, Tigermed Consulting Ltd. joins Sundia Meditech, HD BioSciences, and NovaSecta in their CRO Service Alliance CROSA that provides R&D solutions for pharmaceutical and biotech companies. Tigermed's expertise in clinical development complements the existing drug discovery and pharmaceutical development capabilities of the alliance.

Sundia Meditech, United PharmaTech, and HD BioSciences entered into a CRO Service Alliance in May 2007 in order to quickly and successfully integrate their chemistry and biology expertise for the increased demands from their clients world-wide. Sundia and United merged into one company in the following months. NovaSecta joined the alliance in February 2008 to further integrate the alliance's work with European pharmaceutical and biotech companies.

Tigermed has a strong track record of providing clinical development services, data management and statistical support to multinational and smaller to medium sized pharmaceutical and biotech companies in US, Europe and Asia. Tigermed is also the clear leader in performing clinical trials in China on innovative New Chemical Entities (NCEs), which makes it an excellent potential partner for the pharmaceutical and biotech companies that Sundia, HD BioSciences and NovaSecta work with.

Through the addition of Tigermed to the alliance, clients can now benefit from a seamlessly integrated full R&D service covering discovery, non-clinical and clinical development.

About Sundia Meditech ( http://www.sundia.com )

Sundia MediTech was founded in Shanghai in 2004 by veterans of the US pharmaceutical industry, and is now a leading CRO company in China. The founding team has talent and track record in organic synthesis, medicinal chemistry, drug design and discovery, process chemistry, cGMP API production, in vitro/vivo PK research, formulation development, analytical and bio- analytical areas. Sundia has successfully provided services in custom synthesis, library production, lead optimization (PD and PK), scale up, pre- clinical studies, cGMP API production and pharmaceutical development.

About HD BioSciences ( http://www.hdbiosciences.com )

HD BioSciences, based in Shanghai, is one of the leading biology CRO companies in China. The company is known for its expertise in assay development, high-throughput screening (HTS), hit-to-lead solutions, high- throughput compound profiling, and natural compound-based lead identification. The company's proprietary assays and screening platforms give it a competitive edge in drug lead discovery services and in providing value to its partners and clients from pharmaceutical and biotech companies world-wide.

About NovaSecta ( http://www.novasecta.com )

NovaSecta is a specialist R&D service provider for smaller to mid-sized pharmaceutical and biotech companies ('MidPharmas'). Since its founding in early 2003, NovaSecta has built a unique network of relationships with MidPharmas in Europe and a deep understanding of how these companies manage and develop their R&D capabilities. NovaSecta's current business is originating and managing collaborations for MidPharmas; to date these have included a multi-company R&D program, product/project licensing and acquisitions, and scientific R&D collaborations.

About Tigermed ( http://www.tigermed.net )

Tigermed Consulting Ltd., based in Shanghai, is a leading CRO that specializes in pharmaceutical research and development. It offers a broad range of services including all phases of clinical studies, registration (for chemical and biological drugs, medical devices, etc.), new drug development and technology transfer, data management, GCP training, and market research. Since its founding in 2002, Tigermed has established long-term relationships with many clients in registration and clinical research.

SOURCE Sundia MediTech Company

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.